ClinicalTrials.gg
CompletedNCT05844423Updated Sep 11, 2025

Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

A Phase 2 interventional study of 0.5 ml dose of 1.1 mcg VAX-24 and 0.5 ml dose of PCV20 in Pneumococcal Vaccines, sponsored by Vaxcyte, Inc.. Completed at 32 sites in United States. Open to participants aged 42 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Vaxcyte, Inc. · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
802
Allocation
Randomized
Ages
42 Days to 89 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 344 studies in Pneumonia with a site in United States — 40 open to participants now, 51 under way, 6 of them phase 3. Pneumonia · United States.

Enrollment
35th of 263
802 · median 91
Started
2023
with 14 others
Phase 2
64 of 344
3 open now
Registered
298th of 344
by date
Lead sponsor
5 of 344
Vaxcyte, Inc.

Among the 344 studies in Pneumonia with a site in United States, this one is the 35th largest by enrollment of the 263 interventional ones that give a count, is one of 15 that started in 2023, is one of 64 in phase 2, and was the 298th registered.

Pneumonia

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

40 of the 344 studies in Pneumonia with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.

This study: 42 Days to 89 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 344 studies in Pneumonia with a site in United States, or all of them as a file.
02

Study summary

The objective of the study is to evaluate the safety and tolerability of 4 injections of VAX-24 (at 3 dose levels) compared to PCV15 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll the remainder of the sample size.

03

Conditions studied

  • Pneumococcal Vaccines

Keywords

  • 24 valent PCV
  • Pneumonia
  • Pneumococcal Infection
04

Who can participate

Ages eligible
42 Days to 89 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female infant ≥42 days to ≤89 days (inclusive).
  2. Full-term infant at least 37 weeks gestational age at birth.
  3. Afebrile for ≥72 hours with a rectal temperature \<38.0°C (\<100.4°F) or axillary temperature \<37.8°C (\<100.0°F) before receipt of study vaccine.*
  4. Able to attend all scheduled visits and comply with the study procedures.
  5. Subject's parent/legal guardian is able to read and understands the study procedures, alternate treatments, risks and benefits, and provides written .
  6. Subject's parent/legal guardian is able to fill out an ediary of solicited AE and take daily axillary temperature and measurements of local injection site reactions for the 7 days after each study vaccination.
  7. Subject's parent/legal guardian has an e-mail address and access to a computer or smartphone with internet to complete the ediary.

Exclusion criteria

Exclusion Criteria:

  1. History of invasive pneumococcal disease (positive blood culture, positive cerebrospinal fluid culture, or other sterile site) or known history of other culture positive pneumococcal disease.
  2. Previous receipt of a licensed or vaccine (excluding 1 dose vaccine).
  3. Known to any vaccine.
  4. Known or suspected impairment of immunological function (e.g., asplenia, , primary immunodeficiency).
  5. Use of any therapy (Note: topical and inhaled/nebulized are permitted).
  6. History of failure to thrive.
  7. Subject has a coagulation disorder contraindicating IM vaccination.
  8. Subject or his/her mother have documented hepatitis B surface antigen-positive.
  9. Has a known neurologic or cognitive behavioral disorder.
  10. Has a known congenital malformation or serious chronic disorder.
  11. Receipt of a blood transfusion or blood products, including immunoglobulins.
  12. Receipt of any investigational study product since birth, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study.
  13. Any infant who cannot be adequately followed for safety according to the protocol plan.
  14. Any other reason that in the opinion of the investigator may interfere with the evaluation required by the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
802 participants (actual)

Study arms

  • Experimental
    VAX-24 Low

    Participants will receive 4 doses of VAX-24 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.

    Biological: 0.5 ml dose of 1.1 mcg VAX-24

  • Experimental
    VAX-24 Mid

    Participants will receive 4 doses of VAX-24 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.

    Biological: 0.5 ml dose of 2.2 mcg VAX-24

  • Experimental
    VAX-24 Mixed

    Participants will receive 4 doses of VAX-24 administered as an intramuscular injection at 2, 4, 6, and 12-15 months of age at one of three dose levels.

    Biological: 0.5 ml dose of 2.2/4.4 mcg VAX-24

  • Active comparator
    PCV20

    Participants will receive 4 doses of PCV20 administered as an intramuscular injection of the standard dose at 2, 4, 6, and 12-15 months of age.

    Biological: 0.5 ml dose of PCV20

Interventions

  • Biological0.5 ml dose of 1.1 mcg VAX-24

    24 valent pneumococcal conjugate vaccine

  • Biological0.5 ml dose of PCV20

    20 valent pneumococcal conjugate vaccine

  • Biological0.5 ml dose of 2.2 mcg VAX-24

    24 valent pneumococcal conjugate vaccine

  • Biological0.5 ml dose of 2.2/4.4 mcg VAX-24

    24 valent pneumococcal conjugate vaccine

06

What researchers measure

Primary outcomes

  1. Percentage of participants with any solicited local injection site Adverse Events (AE) within 7 days after each vaccination

    Solicited local reactions include erythema, edema, and tenderness at the injection site

    Time frame: 7 days after each vaccination

  2. Percentage of participants with any solicited systemic AE within 7 days after each vaccination

    Solicited systemic reactions include fever, irritability, decreased appetite, decreased sleep, and increased sleep

    Time frame: 7 days after each vaccination

  3. Percentage of participants with any related Serious Adverse Events (SAE) within 6 months after last vaccination

    Percentage of participants with related SAE

    Time frame: 6 months after last vaccination

Secondary outcomes

  1. Percentage of subjects with any unsolicited AE within 1 month after each vaccination

    Percentage of subjects with any unsolicited AE

    Time frame: 1 month after each vaccination

  2. Percentage of subjects with any unsolicited AE from Dose 1 through 1 month post-Dose 3

    Percentage of subjects with any unsolicited AE between first and 3rd vaccination in the primary series

    Time frame: First vaccination (Dose 1) through 1 month after third vaccination (Dose 3)

  3. Percentage of subjects with any AE resulting in discontinuation of study within 6 months after last vaccination

    Percentage of subjects with any AE resulting in discontinuation of study

    Time frame: 6 months after last vaccination

  4. Percentage of subjects with any new onset of chronic illness (NOCI) within 6 months after last vaccination

    Percentage of subjects with any NOCI

    Time frame: 6 months after last vaccination

  5. Percentage of subjects with any medically attended adverse events (MAAE) within 6 months after last vaccination

    Percentage of subjects with any MAAE

    Time frame: 6 months after last vaccination

  6. Percentage of subjects with any SAE within 6 months after last vaccination

    Percentage of subjects with any SAE

    Time frame: 6 months after last vaccination

  7. Percentage of subjects achieving an anti-pneumococcal Immunoglobulin G (IgG) antibody concentration ≥0.35 mcg/mL 1 month after Dose 3

    Percentage of subjects achieving an anti-pneumococcal IgG antibody concentration ≥0.35 mcg/mL

    Time frame: 1 month after Dose 3

  8. Percentage of subjects achieving an anti-pneumococcal IgG antibody concentration ≥0.35 mcg/mL 1 month after Dose 4

    Percentage of subjects achieving an anti-pneumococcal IgG antibody concentration ≥0.35 mcg/mL

    Time frame: 1 month after Dose 4

  9. IgG antibody Geometric Mean Concentration (GMC) 1 month after Dose 3

    Antibody geometric mean concentrations as measured by IgG for the 24 pneumococcal serotypes in VAX-24

    Time frame: 1 month after Dose 3

  10. IgG antibody GMC 1 month after Dose 4

    Antibody geometric mean concentrations as measured by IgG for the 24 pneumococcal serotypes in VAX-24

    Time frame: 1 month after Dose 4

  11. Opsonophagocytic activity (OPA) Geometric Mean Titer (GMT) 1 month after Dose 3

    Antibody geometric mean titers s as measured by OPA for the 24 pneumococcal serotypes in VAX-24

    Time frame: 1 month after Dose 3

  12. OPA GMT 1 month after Dose 4

    Antibody geometric mean titers s as measured by OPA for the 24 pneumococcal serotypes in VAX-24

    Time frame: 1 month after Dose 4

  13. IgG Geometric Mean Fold Ratio (GMFR) before Dose 4 to 1 month after Dose 4

    Antibody geometric mean fold ratio as measured by IgG for the 24 pneumococcal serotypes in VAX-24

    Time frame: Pre-Dose 4 to 1 month after Dose 4

  14. OPA GMFR before Dose 4 to 1 month after Dose 4

    Antibody geometric mean fold rise as measured by OPA for the 24 pneumococcal serotypes in VAX-24

    Time frame: Pre-Dose 4 to 1 month after Dose 4

  15. Percentage of subjects achieving at least a 4-fold increase in IgG from pre-Dose 4 to 1 month post Dose 4

    Geometric mean concentration with a at least a 4-fold increase in IgG antibodies for the 24 pneumococcal serotypes in VAX-24

    Time frame: Pre-Dose 4 to 1 month after Dose 4

  16. Percentage of subjects achieving at least a 4-fold increase in OPA titers from pre-Dose 4 to 1 month post Dose 4

    Geometric mean titer with a at least a 4-fold increase in OPA titers for the 24 pneumococcal serotypes in VAX-24

    Time frame: Pre-Dose 4 to 1 month after Dose 4

07

Study locations

32 sites
  • The Children's Clinic of Jonesboro, P.A.
    Jonesboro, Arkansas 72401, United States
  • Madera Family Medical Group
    Madera, California 93637, United States
  • Jedidiah Clinical Research
    Tampa, Florida 33617, United States
  • Kentucky Pediatric/ Adult Research
    Bardstown, Kentucky 40004, United States
  • ACC Pediatric Research
    Haughton, Louisiana 71037, United States
  • Meridian Clinical Research
    Hastings, Nebraska 68901, United States
  • Midwest Children's Health Research Institute
    Lincoln, Nebraska 68504, United States
  • Midwest Children's Health Research Institute
    Lincoln, Nebraska 68505, United States
  • Midwest Children's Health Research Institute
    Lincoln, Nebraska 68516, United States
  • Midwest Children's Health Research Institute
    Lincoln, Nebraska 68522, United States
  • Ohio Pediatric Research Assn.
    Dayton, Ohio 45414, United States
  • UPMC Bass Wolfson Cranberry
    Cranberry Township, Pennsylvania 16066, United States
  • Allegheny Health and Wellness Pavilion
    Erie, Pennsylvania 16506, United States
  • UPMC Children's Community Pediatrics South Hills-Jefferson Hills
    Jefferson Hills, Pennsylvania 15025, United States
  • UPMC Primary Care Center Oakland
    Pittsburgh, Pennsylvania 15213, United States
  • UPMC Children's Community Pediatrics Bass Wolfson-Squirrel Hill
    Pittsburgh, Pennsylvania 15217, United States
  • UPMC Children's Community Pediatrics-Castle Shannon
    Pittsburgh, Pennsylvania 15234, United States
  • Palmetto Pediatrics, PA
    North Charleston, South Carolina 29406, United States
  • Tribe Clinical Research at Parkside Pediatrics
    Simpsonville, South Carolina 29680, United States
  • Coastal Pediatric Research
    Summerville, South Carolina 29486, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Ventavia Research Group
    Burleson, Texas 76028, United States
  • Ventavia
    Houston, Texas 77008, United States
  • Kool Kids Pediatrics
    Houston, Texas 77065, United States
  • Pediatric Associates
    Houston, Texas 77087, United States
  • Pediatric Center
    Richmond, Texas 77469, United States
  • Alliance for Multispecialty Research
    Layton, Utah 84041, United States
  • Alliance for Multispecialty Research
    Murray, Utah 84107, United States
  • Alliance for Multispecialty Research
    Provo, Utah 84604, United States
  • Alliance for Multispecialty Research
    Roy, Utah 84067, United States
  • Alliance for Multispecialty Research
    Syracuse, Utah 84075, United States
  • Pediatric Research of Charlottesville, LLC
    Charlottesville, Virginia 22902, United States
08

References and documents

Individual participant data

Plan to share: Yes — Vaxcyte is committed to providing access to anonymized data from the company's clinical trials for the purpose of legitimate scientific research. Requests for data may be addressed to datasharing@vaxcyte.com. Requests must be accompanied by a detailed analysis plan and will be reviewed for scientific validity. Data will be made available after initial product approval. Sharing of data may require execution of a data-sharing agreement.

Supporting information: Study protocol

Time frame: Individual participant data will be shared after deidentification and made available starting 6 months after initial product approval.

Access criteria: Criteria will depend on the specific proposal received and may include qualification of the scientific researchers, potential contribution to the research field, scientific rigor of statistical and analytical methods, and other criteria appropriate for the proposal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Aug 2025, 28 months.

Of 65 phase 2 interventional studies under Pneumonia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 28 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
May 6, 2023
StartActual
Mar 29, 2023
Primary completionActual
Aug 25, 2025
CompletionActual
Aug 25, 2025
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05844423
Lead sponsor
Vaxcyte, Inc.
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Mar 29, 2023
Primary completion
Aug 25, 2025
Completion
Aug 25, 2025
Last update
Sep 11, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion